Trials / Completed
CompletedNCT00332917
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 224 (actual)
- Sponsor
- Solvay Pharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pardoprunox | 12-42 mg |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2006-06-02
- Last updated
- 2009-01-26
Locations
130 sites across 21 countries: United States, Argentina, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Finland, India, Israel, Mexico, New Zealand, Peru, Romania, Russia, Serbia, Slovakia, South Africa, Sweden, Ukraine
Source: ClinicalTrials.gov record NCT00332917. Inclusion in this directory is not an endorsement.